Abstract
Apoptosis is associated with caspase-mediated proteolysis of Type I (K18 and K19) cytokeratins. We previously showed a positive association between the levels of tissue polypeptide antigen (TPA), that recognizes cytokeratins K8, K18, and K19 fragments, and induced apoptosis in breast cancer cell lines. The aim of the present study was to evaluate the interrelationships between TPA, steroid receptors, and p53, and their joint prognostic role in node-negative breast cancer patients not treated with adjuvant therapies. Age and pT were also considered since they are known prognostic factors. Five hundred and ninety-nine cases with N- breast cancer were evaluated (median follow-up: 60 months). TPA was measured by an immunoradiometric assay and p53 by an immuno-chemiluminescent assay in tumor cytosol. Multiple correspondence analysis was used to study the associations among variables. Their prognostic role (univariate analysis) and their joint effect (multivariate analysis) on RFS were investigated with Cox regression models. TPA showed a direct association with ER and PgR. Higher p53 values were weakly associated to low values of ER, PgR, and TPA. Younger age was related to low and intermediate values of ER and PgR and to low p53 values, while older age was related to high values of ER. Multivariate analysis showed a significant prognostic impact for pT, age, ER, and TPA. Among the interactions considered clinically relevant, only that between ER and age was found. RFS estimated values were poorer in cases with lower than in those with higher TPA values, both in patients expected to have a poor (pT2, young age, low ER) and a better prognosis (pT1, older age, high ER). From the findings of the present study we can draw the following conclusions: The relationship of TPA with prognosis gives an additional contribution to pT, age, and steroid receptors in N- breast cancer; TPA may be considered the first marker of apoptosis measured with a fully standardized quantitative method in tumor cytosol and could be evaluated in prognostic indexes including markers related to different biological mechanisms.
Similar content being viewed by others
References
Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13: 697–704, 1995
Goldhirsch A, Glick JH, Gelber RD, Seen HJ: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer I 90: 1601, 1998
Gasparini G: Prognostic variables in node-negative and nodepositive breast cancer – editorial. Breast Cancer Res Treat 52: 321–331, 1998
Ellis LM, Walker RA, Gasparini G: Is determination of angiogenic activity in human tumours clinically useful? Eur J Cancer 34(5): 609–618, 1998
Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer I 89: 139–147, 1997
Toi M, Gion M, Biganzoli E, Dittadi R, Boracchi P, Miceli R, Meli S, Mori K, Tominaga T, Gasparini G: Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications. Angiogenesis 1: 71–83, 1997
Dittadi R, Brazzale A, Pappagallo G, Salbe C, Nascimben O, Rosabian A, Gion M: ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 17: 1245–1248, 1997
Koscielny S, Terrier P, Spielmann M, Delarue JC: Prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer I 90(9): 712, 1998
Coradini D, Biganzoli E, Boracchi P, Bombardieri E, Seregni E, De Palo G, Martelli G, Di Fronzo G: Effect of steroid receptors, pS2 and cathepsin D on the outcome elderly breast cancer patients: an exploratory investigation. Int J Cancer 79(4): 305–311, 1998
Dittadi R, Biganzoli E, Boracchi P, Salbe C, Mione R, Gatti C, Gion M: Impact of steroid receptors, pS2 and cathepsin D on the outcome of NC postmenopausal breast cancer patients treated with tamoxifen. Int J Biol Mark 13(1): 30–41, 1998
Biganzoli E, Boracchi P, Daidone MG, Gion M, Marubini E: Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Mark 13: 107–123, 1998
Osborne C: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51: 227–238, 1998
Hupperets PS, Volovics L, Schouten LJ, Jager JJ, Schouten HC, Hillen HF, Blijham GH: The prognostic significance of steroid receptor activity in tumor tissue of patients with primary breast cancer. Am J Clin Oncol 20(6): 546–551, 1997
Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66: 71–141, 1995
Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. Immunohistochemistry 4(2): 106–116, 1996
Bates S, Vousden KH: Mechanisms of p53-mediated apoptosis. Cell Mol life Sci 55(1): 28–37, 1999
Hockenbery D: Defining apoptosis. Am J Pathol 146(1): 16, 1995
Ellis RE, Yuan J, Horvitz HR: Mechanism and function of cell death. Ann Rev Cell Biol 7: 663–698, 1991
Sanders EJ: Methods for detecting apoptotic cells in tissues. Histol Histopathol 12(4): 1169–1177, 1997
Ku NO, Liao J, Omary MB: Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272(52): 33197–33203, 1997
Dittadi R, Coradini D, Meo S, Pirronello E, Daidone MG, Gion M: Tissue polypeptide antigen as a putative indicator of apoptosis. Clin Chem 44(9): 2002–2003, 1998
Gion M, Mione R, Gatti C, Dittadi R, Leon AE, Castiglioni C, Nascimben O, Bruscagnin G: Tissue polypeptide antigen in tumor cytosol: a new prognostic indicator in primary breast cancer. Breast Cancer Res Treat 17: 15–21, 1990
Veronesi U, Salvadori B: Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1, 973 patients. Eur J Cancer 31: 1574–1579, 1995
Gion M, Dittadi R, Leon AE, Bruscagnin G, Pelizzola D, Giovannini G, Giganti M, Messeri G, Quercioli M, Flamini E, Riccobon A, Bozzetti C, Benecchi M, De Lena M, Paradiso A, Ruggeri G, Luisi P, Piffanelli A: Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: a multicenter study. Eur J Cancer 27(8): 996–1002, 1991
EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in humanbreast cancer; report of the second EORTC Workshop. Eur J Cancer 16: 1513–1515, 1980
Dittadi R, Brazzale A, Mione R, Di Fresco S, Gatti C, Vinante O, Bassan F, Nascimben O, Gion M: Quantitative chemiluminescent immunoassay of p53: prognostic significance in 220 node-negative breast cancer tissue. Anticancer Res 17: 4691–4696, 1997
Greenacre MJ: Correspondence Analysis in practice. Academic Press, London, 1996
Benzecrì JP: Sur le calcul des taux d'inertie dans l'analyse d'un questionnaire. Le Cahiers de l'Analyse des Données 4: 377–383, 1979
Lebart L, Morineau A, Piron M: Statistique exploratoire multidimensionelle. Dunod, Paris, 1995
Grambsch P, Therneau T: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515–526, 1994
Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med 8: 551–561, 1989
Thorpe SM: Estrogen and progesterone receptor determinations in breast cancer. Tecnology, biology and clinical significance. Acta Oncol 27(1): 1–19, 1988
Wilking N, Rutqvist E, Nordenskjöld B, Skoog L: Steroid receptor levels in breast cancer. Relationship with age and menopausal status. Acta Oncol 28: 807–810, 1989
Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Nat Cancer Inst 85: 965–970, 1993
Sauerbrei W, Schumacher M: A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11: 2093–2109, 1992
Harrel FE, Lee KL, Mark DB: Tutorial in biostatistics multivariable prognostic model: issues in developing models, evaluating assumption and adequacy, and measuring and reducing errors. Stat Med 15: 361–387, 1996
Altman DG, De Stavola BL, Love SB, Stepniewska KA: Review of survival analyses published in cancer journals. Brit J Cancer 72: 551–558, 1995
Altman DG, Lausen B, Sauerbrei W, Schumaker M: Danger of using ‘optimal’ cutpoints in the evaluation of prognostic factors. J Natl Cancer I 86: 829–835, 1994
Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Brandes A, Vinante O, Bruscagnin G: Tissue polypeptide antigen in breast cancer cytosol. A new effective prognostic indicator. Eur J Cancer 29A(1): 66–69, 1993
Gion M, Mione R, Dittadi R, Fasan S, Pallini A, Bruscagnin G: Carcinoembryonic antigen, ferritin and tissue polypeptide antigen in serum and tissue. Relationship with the receptor content in breast carcinoma. Cancer 57(5): 917–922, 1986
Gion M, Mione R, Becciolini A, Balzi M, Correale M, Piffanelly A, Giovannini G, Saccani Jotti G, Fontanesi M: Relationship between cytosol TPS, TPA and cell proliferation. Int J Biol Mark 9(2): 109–114, 1994
Gion M, Mione R, Barioli P, Sartorello P, Capitanio G: Tissue polypeptide antigen and tissue polypeptide specific antigen in primary breast cancer. Evaluation in serum and tumour tissue. Eur J Clin Chem Clin Biochem 32: 779–787, 1994
Neville AM, Bettelheim R, Gelber RD, Save-Soderbergt J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN, Isley M, Rudenstam CM, Collins J, Castiglione M, Senn HJ, Goldhrisch A: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 10(5): 696–705, 1992
Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouh R, Save-Soderbergh J, Holloway L, Russel I, Rudenstam M: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58: 2662–2670, 1986
Caulìn C, Salvesen GS, Oshima RG: Caspase cleavage of keratin 18 and reorganisation of intermediate filaments during epithelial cell apoptosis. J Cell Biol 136(6): 1379–1394, 1997
Mellerik DM, Osborn M, Weber K: On the nature of serological tissue polypeptide antigen (TPA): monoclonal keratin 8, 18, 19 antibodies react differently with TPA prepared from human serum. Oncogene 5: 100–117, 1990
Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1–16, 1997
Leers MPG, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FCS, Björklund B, Nap M, Jörnvall H, Schutte B: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol, 1999 (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gion, M., Boracchi, P., Dittadi, R. et al. Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis. Breast Cancer Res Treat 59, 211–221 (2000). https://doi.org/10.1023/A:1006318112776
Issue Date:
DOI: https://doi.org/10.1023/A:1006318112776